Understanding kidney changes in Fabry disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the natural history of kidney changes in patients with Fabry disease before they start enzyme replacement therapy. It will analyze kidney biopsies to identify microscopic structural changes and correlate these with kidney function metrics such as glomerular filtration rate and urinary albumin excretion. The study seeks to establish a clearer understanding of how kidney injury progresses in Fabry patients, potentially leading to better early intervention strategies. By focusing on untreated patients, the research will provide insights into the disease's progression and its impact on kidney health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients diagnosed with Fabry disease who have/have not received enzyme replacement therapy where a clinical decision has been made to obtain a kidney biopsy, a GFR, and urinary albumin studies or where patients have previously completed clinical trials which included measures of renal function and renal biopsies.

Exclusion Criteria:

* Patients with serum creatinine more than 2.5 mg/dL or known to have a renal disease other than Fabry.

Where it's running

• University of Minnesota
  Minneapolis, Minnesota, United States Recruiting
• Universtity of Minnesota, Department of Pediatric Nephrology
  Minneapolis, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Chet Whitley, MD — University of Minnesota
• Study coordinator: Michael Mauer, MD
• Email: mauer002@umn.edu
• Phone: 612-626-2720

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lucerastat in untreated adult men with Fabry disease shows how well it works and safety

  This study tests lucerastat to see if it can reduce Gb3 buildup and be safe in untreated adult men with Fabry disease.

  Recruiting Phase 3 Idorsia Pharmaceuticals Ltd. · Birmingham, Alabama and 15 other locations · NCT07778667

• Periodontal Health in Rare Kidney Conditions and Controls

  This study tests how common periodontitis is in people with rare kidney disorders and compares it to CKD patients and people without kidney disease.

  Recruiting Institutul Clinic Fundeni · Bucharest · NCT07575347

• Anderson-Fabry disease fitness improvement program

  This study tests whether a 12-week physiotherapy-led exercise program can improve function, fitness, strength, and quality of life in adults with Fabry disease.

  Recruiting General University Hospital, Prague · Prague · NCT07495410

• Using advanced heart MRI to improve diagnosis and risk prediction for rare cardiomyopathies

  This project tests whether advanced cardiac MRI techniques can help diagnose and predict future risk for people with rare heart muscle diseases like Danon, Fabry, cardiac amyloidosis, Noonan syndrome, and cardiac sarcoidosis.

  Recruiting Chinese Academy of Medical Sciences, Fuwai Hospital · Beijing · NCT07336394

• Quality of life for people 65+ with Fabry disease, treated or untreated

  This project will see if starting or continuing Fabry disease treatment changes quality of life over two and five years in people aged 65 and older.

  Recruiting Groupe Hospitalier Diaconesses Croix Saint-Simon · Paris, France · NCT07277361

• Agalsidase alfa for heart inflammation in Fabry disease measured by PET‑CMR

  This study will test whether agalsidase alfa reduces heart inflammation in people with Fabry disease by comparing PET‑CMR scans before and after 12 months of treatment.

  Recruiting Yonsei University · Seoul · NCT07235709

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.